Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus gemcitabine/cisplatin as neoadjuvant therapy for locally advanced bladder cancer
ChiCTR2000032359Phase 2Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Mar 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of camrelizumab in bladder cancer and transitional cell carcinoma (TCC) (3 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Pathological complete response. Started Mar 2020; status: recruiting.
02
Drugs
camrelizumab
03
Conditions
bladder cancertransitional cell carcinoma (TCC)
Beyond the preview
Go deeper on ChiCTR2000032359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000032359.